Skip to content
Sonata(zaleplon)
Sonata, Zerene (zaleplon) is a small molecule pharmaceutical. Zaleplon was first approved as Sonata on 1999-03-12. It is used to treat sleep initiation and maintenance disorders in the USA. It has been approved in Europe to treat sleep initiation and maintenance disorders.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
mental disordersD001523
Trade Name
FDA
EMA
Sonata (generic drugs available since 2008-06-06)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Zaleplon
Tradename
Company
Number
Date
Products
SONATAMylanN-020859 RX1999-08-13
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
zaleplonANDA2019-08-26
zaleplonANDA2019-08-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
sleep initiation and maintenance disorders—D007319F51.01
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05C: Hypnotics and sedatives
— N05CF: Benzodiazepine related hypnotics and sedatives
— N05CF03: Zaleplon
HCPCS
No data
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2061781940
Hemophilia aD006467EFO_0007267D66———1—1
Parkinson diseaseD010300EFO_0002508G20———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Progressive multifocal leukoencephalopathyD007968EFO_0007455A81.2—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526B19.21————1
Kaposi sarcomaD012514C461————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameZALEPLON
INNzaleplon
Description
Zaleplon is a pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position. It has a role as an anticonvulsant, a central nervous system depressant, a sedative and an anxiolytic drug. It is a pyrazolopyrimidine and a nitrile.
Classification
Small molecule
Drug classnon-benzodiazepine anxiolytics, sedatives, hypnotics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1
Identifiers
PDB—
CAS-ID151319-34-5
RxCUI74667
ChEMBL IDCHEMBL1521
ChEBI ID10102
PubChem CID5719
DrugBankDB00962
UNII IDS62U433RMH (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,041 documents
View more details
Safety
Black-box Warning
Black-box warning for: Zaleplon, Zaleplon
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
203 adverse events reported
View more details